Paclitaxel and its evolving role in the management of ovarian cancer

Kampan, N, Madondo, M, McNally, O, Quinn, M and Plebanski, M 2015, 'Paclitaxel and its evolving role in the management of ovarian cancer', BioMed Research International, vol. 2015, 413076, pp. 1-21.


Document type: Journal Article
Collection: Journal Articles

Title Paclitaxel and its evolving role in the management of ovarian cancer
Author(s) Kampan, N
Madondo, M
McNally, O
Quinn, M
Plebanski, M
Year 2015
Journal name BioMed Research International
Volume number 2015
Article Number 413076
Start page 1
End page 21
Total pages 21
Publisher Hindawi Publishing Corporation
Abstract © 2015 Nirmala Chandralega Kampan et al. Paclitaxel, a class of taxane with microtubule stabilising ability, has remained with platinum based therapy, the standard care for primary ovarian cancer management. A deeper understanding of the immunological basis and other potential mechanisms of action together with new dosing schedules and/or routes of administration may potentiate its clinical benefit. Newer forms of taxanes, with better safety profiles and higher intratumoural cytotoxicity, have yet to demonstrate clinical superiority over the parent compound.
Subject Immunology not elsewhere classified
DOI - identifier 10.1155/2015/413076
Copyright notice © 2015 Nirmala Chandralega Kampan et al.
ISSN 2314-6133
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 62 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 0 times in Scopus Article
Altmetric details:
Access Statistics: 11 Abstract Views  -  Detailed Statistics
Created: Thu, 06 Dec 2018, 10:39:00 EST by Catalyst Administrator
© 2014 RMIT Research Repository • Powered by Fez SoftwareContact us